This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Malignant Pleural Effusion industry.
What is the current market size of the malignant pleural effusion industry, and what growth rate is it expected to achieve?
The malignant pleural effusion market size has grown strongly in recent years. It will grow from $4.42 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the growing adoption of indwelling pleural catheters, increased focus on palliative allative care, increasing clinical trials, rising reimbursement, and rising metastatic malignancies.
The malignant pleural effusion market size is expected to see strong growth in the next few years. It will grow to $6.17 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing healthcare infrastructure, rising government support, increasing cancer survivors, rising demand for home-based care, growth in liquid biopsy. Major trends in the forecast period include the integration of artificial intelligence in imaging tools, advancements in targeted cancer therapies, advancements in pleurodesis, improvements in biomarkers, and expanding clinical trials for novel therapeutic agents.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22047&type=smp
What are the major drivers contributing to the growth of the malignant pleural effusion market?
The rising cases of lung cancer is expected to propel the growth of the malignant pleural effusion market going forward. Lung cancer is a disease characterized by the uncontrolled growth of abnormal cells in the lungs, which can form tumors and interfere with normal lung function. The rising cases of lung cancer are due to smoking and tobacco use, as prolonged exposure to harmful chemicals in cigarettes damages lung tissues, triggers genetic mutations, and promotes the uncontrolled growth of cancerous cells, significantly increasing the likelihood of developing the disease. Malignant pleural effusion indicates advanced lung cancer progression by facilitating tumor spread within the pleural cavity, leading to worsened respiratory function and a poorer prognosis. For instance, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organizations company, the estimated number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the estimated deaths were 130,180 in 2022 and 127,070 in 2023. Therefore, the rising cases of lung cancer is driving the growth of the malignant pleural effusion market.
Impact Of Improving Healthcare Infrastructure On The Market Due To Enhanced Diagnosis And Treatment Accessibility
The improving healthcare infrastructure is expected to propel the growth of the malignant pleural effusion market going forward. Healthcare infrastructure refers to the physical, technological, and organizational structures required for delivering healthcare services, including hospitals, clinics, medical equipment, IT systems, and workforce. Improving healthcare infrastructure is attributed to need for better disease management, all of which contribute to enhanced healthcare accessibility, efficiency, and quality of care. Improving healthcare infrastructure enhances the diagnosis, treatment, and management of malignant pleural effusion by enabling access to advanced medical technologies, better-equipped healthcare facilities, and specialized care, ultimately improving patient outcomes. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the number of hospitals in the United States increased by 0.591% from the previous year, rising from 6,093 to 6,129. Therefore, the improving healthcare infrastructure is driving the growth of the malignant pleural effusion market.
What are the major market segments driving the growth of the malignant pleural effusion industry?
The malignant pleural effusion market covered in this report is segmented –
1) By Treatment: Systemic Therapy, Therapeutic Thoracentesis, Thoracic Drainage And Pleurodesis, Indwelling Pleural Catheter
2) By Diagnosis: Pleural Fluid Cytology, Immunohistochemical Tests, Imaging Tests, Pleural Thoracentosis, Pleuroscopy, Pleural Biopsy
3) By End Users: Hospitals, Ambulatory Clinics, Other End Users
Subsegmentss:
1) By Systemic Therapy: Chemotherapy, Targeted Therapy, Immunotherapy
2) By Therapeutic Thoracentesis: Single-Time Thoracentesis, Repeated Thoracentesis
3) By Thoracic Drainage And Pleurodesis:Chemical Pleurodesis, Mechanical Pleurodesis, Biological Pleurodesis
4) By Indwelling Pleural Catheter:Tunneled Pleural Catheter, Non-Tunneled Pleural Catheter
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/malignant-pleural-effusion-global-market-report
What are the most notable trends influencing investment in the malignant pleural effusion sector?
Major companies operating in the malignant pleural effusion market are focusing on developing innovative therapies such as enzyme-targeting therapy to improve treatment outcomes by targeting specific enzymes involved in fluid accumulation. Enzyme-targeting therapy is a medical approach that involves designing drugs or treatments to specifically inhibit or modify the activity of enzymes associated with diseases. This therapy is commonly used in conditions such as cancer, metabolic disorders, and infectious diseases, where abnormal enzyme activity contributes to disease progression. For instance, in September 2022, RS Oncology, LLC, a US-based biotechnology company, Initiated the MITOPE clinical trial, a first-in-human Phase 1/2 trial conducted in the United Kingdom. This study is a Phase 1/2 trial assessing RSO-021, a novel PRX3 inhibitor designed to treat malignant pleural effusion and mesothelioma by targeting oxidative stress to eliminate cancer cells while preserving healthy tissue.
Who are the key market players contributing to the growth of the malignant pleural effusion industry?
Major companies operating in the malignant pleural effusion market are Pfizer Inc., Merck & Co. Inc., Novartis International AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Amgen Inc., Medline Industries LP, Becton Dickinson and Company, Cook Medical LLC, Merit Medical Systems Inc., Argon Medical Devices Inc., B Braun SE, Simcere Pharmaceutical Group Limited, pfm medical AG, Redax SpA, Wuhan YZY Biopharma Co. Ltd., Rocket Medical plc, Genelux Corporation, Gongwin Biopharm Holdings Co. Ltd., Ewimed GmbH
Which regions are leading the growth of the malignant pleural effusion market globally?
North America was the largest region in the malignant pleural effusion market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant pleural effusion market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Malignant Pleural Effusion Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22047
Need Customized Data On Malignant Pleural Effusion Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=22047&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
